EHR Alerts Trigger Primary Care Clinics to Improve Hypertension Care in CKD
(MedPage Today) -- A computerized clinical decision support (CDS) tool for primary care helped lower blood pressure (BP) in patients with chronic kidney disease (CKD) and uncontrolled hypertension, a cluster-randomized trial found. When primary... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 15, 2024 Category: Cardiology Source Type: news

Chart Flag Boosts BP Control in Kidney Patients Chart Flag Boosts BP Control in Kidney Patients
Clinical decision support systems could be a promising tool to help clinicians control hypertension in patients with chronic kidney disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 14, 2024 Category: Consumer Health News Tags: Family Medicine/Primary Care Source Type: news

Nigeria: Overcoming Barriers to Kidney Health in Nigeria - - World Kidney Day 2024
[Nigeria Health Watch] Salisu Hauwa, a 33-year-old woman in Gashau, a Local Government Area (LGA) in northern Yobe State, Nigeria was diagnosed with chronic kidney disease (CKD) at the Yobe State University Teaching Hospital (YSUTH) in Damaturu. This diagnosis came weeks after she had been experiencing headaches and continuous vomiting. According to her husband, Abubakar Mohammed, Hauwa's condition worsened, as she was constantly screaming, biting, and attempting to run away from the hospital leading some to believe that she (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 13, 2024 Category: African Health Tags: Health and Medicine Nigeria West Africa Source Type: news

Risk for Rapid Progression Explored in Patients With CKD Stage G3
WEDNESDAY, March 13, 2024 -- Individuals with incident chronic kidney disease (CKD) stage G3 have a 14.6 percent three-year risk for rapid progression, according to a study recently published in Nephrology Dialysis Transplantation.Anne H.S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2024 Category: Pharmaceuticals Source Type: news

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news

Novo Kidney Trial Finds Ozempic Cuts Cardiac Risks in Diabetics Novo Kidney Trial Finds Ozempic Cuts Cardiac Risks in Diabetics
Novo Nordisk ' s widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study found, cutting the risk of...Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 5, 2024 Category: Surgery Tags: Diabetes & Endocrinology Source Type: news

Novo Kidney Trial Finds Ozempic Cuts Cardiac Deaths in Diabetics Novo Kidney Trial Finds Ozempic Cuts Cardiac Deaths in Diabetics
Novo Nordisk ' s widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study found, cutting the risk of...Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 5, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

Mayo Clinic Minute: Why Black Americans are at higher risk of chronic kidney disease
Chronic kidney disease is a condition where your kidneys lose their ability to filter waste and fluid from your blood. This can lead to serious health problems such as heart disease, stroke and kidney failure.The Black community faces a higher risk of chronic kidney disease. This can be due to genetics, higher rates of hypertension and diabetes, and socioeconomic issues such as access to healthcare and structural racism.  Dr. Ivan Porter II, a Mayo Clinic nephrologist, says these factors create a… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 5, 2024 Category: Databases & Libraries Source Type: news

Gout increases the risk of multiple diseases
A study shows that gout not only increases the risk of a broad range of cardiovascular diseases it also leads to a higher prevalence of other health conditions, including chronic kidney disease, high blood pressure and an increased Body Mass Index (BMI). Researchers from the Universities of Oxford, Glasgow, and KU Leuven in Belgium found... Read moreThe post Gout increases the risk of multiple diseases appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - February 22, 2024 Category: Nursing Authors: Carolyn Scott Tags: Cardiology Older people care gout Source Type: news

Drug Trials Snapshots: JESDUVROQ
JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor that treats anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 22, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Risk of fall in patients with chronic kidney disease: results from the China Health and Retirement Longitudinal Study (CHARLS) - Lin P, Wan B, Zhong J, Wang M, Tang F, Wang L, Guo J, Ye Y, Liu X, Peng L, Deng L.
BACKGROUND: Chronic kidney disease (CKD), often coexisting with various systemic disorders, may increase the risk of falls. Our study aimed to assess the prevalence and risk of falls among patients with CKD in China. METHODS: We included patients w... (Source: SafetyLit)
Source: SafetyLit - February 19, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

​​Boehringer's Jardiance now gets CDSCO nod for chronic kidney disease
The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of chronic kidney disease (CKD). This approval allows nephrologists and cardiologists to use Jardiance for eligible CKD patients, reducing hospitalizations and addressing unmet medical needs. (Source: The Economic Times)
Source: The Economic Times - February 14, 2024 Category: Consumer Health News Source Type: news

'Miracle' weight-loss drugs could halt kidney disease too
People with chronic kidney disease could become the latest patients offered Weight-loss jabs such as Ozempic and Wegovy on the NHS, as the health service tries to combat the growing problem. (Source: the Mail online | Health)
Source: the Mail online | Health - February 11, 2024 Category: Consumer Health News Source Type: news

Exercise reduces risk of kidney disease in patients with type 2 diabetes
Regular bouts of moderate to vigorous activity can protect patients with type 2 diabetes from developing kidney disease, a research study has found. Overweight and obese people with type 2 diabetes who undertook moderate to vigorous physical activity every week were significantly less likely to progress to chronic kidney disease than those who undertook minimal... Read moreThe post Exercise reduces risk of kidney disease in patients with type 2 diabetes appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - February 8, 2024 Category: Nursing Authors: Carolyn Scott Tags: Diabetes chronic kidney disease Exercise Source Type: news